期刊文献+

辛伐他汀治疗原发性肾病综合征高脂血症30例临床观察 被引量:3

Effect of Simvastatin on hyperlipidemia of primary nephritic syndrome:30 cases observation
下载PDF
导出
摘要 目的:观察辛伐他汀治疗原发性肾病综合征高脂血症的临床效果。方法:将原发性肾病综合征患者60例随机分为观察组与对照组,每组30例,对照组给予标准激素治疗,观察组在标准激素治疗的基础上加用辛伐他汀,治疗3周后分别检测两组患者的总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平及24 h尿蛋白定量(24 h UPQ)情况。结果:两组治疗后24 h UPQ均明显低于治疗前(P<0.01),观察组治疗后TC、LDL-C水平明显低于治疗前和对照组(P<0.01)。结论:辛伐他汀治疗原发性肾病综合征高脂血症有较好的临床疗效。 Objective: To observe of Simvastatin on hyperlipidemia of primary nephritic syndrome. Methods: Randomly separated 60 patients with primary nephritic syndrome into observation group and control group, with 30 patients per group. Treated the control group with standard hormone therapy, while treated observa- tion group with Simvastatin and standard hormone. After 3 weeks, tested the status of total cholesterol (TC), tri- glyceride (TG), high density lipoprotein-cholesterol ( HDL-C), low density lipoprotein cholesterol (LDL-C) and 24h urinary protein quantification (24h UPQ) in both two groups. Results: After treatment, the levels of 24 h UPQ declined significantly in both two groups (P 〈 0.01 ), while the level of TC, and LDL-C in observation group decreased significantly, too (P 〈 0.01 ). Conclusion: Simvastatin is effective on hyperlipidemia of primary nephritic syndrome.
出处 《海南医学院学报》 CAS 2009年第4期355-356,共2页 Journal of Hainan Medical University
关键词 原发性肾病综合征 高脂血症 辛伐他汀 Primary nephritic syndrome Hyperlipidemia Simvastatin
  • 相关文献

参考文献6

二级参考文献34

  • 1American diabetes association. Dyslipidemia management in adults with diabetes[ J ]. Diabetes Care, 2004, 27 (Suppl) : S68. 被引量:1
  • 2Worz C R, Bottorff M. Treating dyslipidemic patients with lipid modifying and combination therapies[J]. Pharrmcotherapy, 2003, 23(5): 625. 被引量:1
  • 3Snow V, Aronson M D, Hombake E R, et al. Lipid control in the managent of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians[J ]. Ann Intern Med, 2004, 140: 644. 被引量:1
  • 4Wierzbicki A S, Mikhailidis D P, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review[J]. Curr Med Res Opin, 2003, 19(3) : 155. 被引量:1
  • 5Fruchart J C. Peroxiisome proliferators-activatde recptor-alpha activation and high- density lipoprotein metabolism [ J ]. Am J Cardiol, 2001, 88(12A): 24N. 被引量:1
  • 6Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL[J]. J Cin Invest, 2001 107: 1423. 被引量:1
  • 7Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs[J]. Toxicol Lett, 2002, 128: 159. 被引量:1
  • 8苏颖,中华肾脏病杂志,1998年,14卷,215页 被引量:1
  • 9于力,中华肾脏病杂志,1997年,13卷,14页 被引量:1
  • 10Moorhead JF, Chan MK, Nahas ME. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease[J]. Lancet, 1982, 2(8 311):1 309. 被引量:1

共引文献92

同被引文献40

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部